Please login to the form below

Not currently logged in

Sanofi and GSK share positive data for two COVID-19 booster vaccine trials

Both the COVIBOOST and phase 3 VAT02 trials showed the booster was well-tolerated, with favourable safety profiles


Sanofi and GSK have jointly developed a next-generation COVID-19 booster vaccine candidate, based on Sanofi’s recombinant Beta variant antigen and combined with GSK’s pandemic adjuvant. Both have served as established vaccine platforms that have proven successful against influenza.

In the phase 3 VAT02 cohort 2 trial, the Sanofi/GSK vaccine candidate caused – at day 15 post-immunisation – a significant boost in antibody titres above baseline against multiple variants of concern in adults who previously received mRNA COVID-19 vaccinations.

Specifically against Omicron, the preliminary data demonstrated 40 times as much of an increase against the BA.1 variant.

In addition to this, the Sanofi/GSK booster produced twice the number of neutralising antibodies against Omicron BA.1 and BA.2 when compared to the original parent virus booster.

Thomas Triomphe, executive vice president, Sanofi Vaccines, said: “COVID-19 keeps evolving and the combination of emergence of variants and waning immunity is likely to lead to the need for additional booster shots, at least in some populations. The Beta variant expresses similar mutations across multiple variants of concern, including Omicron, making it a strong vaccine candidate to confer broad protection against multiple strains of COVID-19.

“Seeing the cross-neutralisation data from the independent AP-HP study, we believe this next-generation booster could have an important role to play for public health vaccination campaigns. We look forward to submitting the data to global regulatory authorities.”

The independent COVIBOOST study showed that, following a primary vaccination with two doses of Pfizer/BioNTech’s Comirnaty vaccine, the Sanofi/GSK booster resulted in a higher immune response than Pfizer/BioNTech’s booster or the Sanofi/GSK first-generation booster, both targeting the original D614 parent strain.

The COVIBOOST trial, conducted by Assistance Publique, Hôpitaux de Paris, involved 247 participants and reported that all three vaccines elicited neutralising antibodies against the Omicron BA.1 strain, with the highest responses coming from the Sanofi/GSK booster.

Both studies showed the Sanofi/GSK next-generation vaccine was well-tolerated, with a favourable safety profile, while in the VAT02 cohort 2 study, less than 4% of grade 3 reactions were reported, all noted as being transient and non-severe.

The partnership plans to submit the data to regulatory authorities in the coming weeks, with the goal of making it available later in 2022.

Article by
Fleur Jeffries

13th June 2022

From: Research, Regulatory, Healthcare



Subscribe to our email news alerts

Featured jobs


Add my company
Graphite Digital

We’re a digital CX agency collaborating with healthcare and pharmaceutical organisations to help them connect more deeply with their audiences...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....